The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas.

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-11-01 DOI:10.1002/hed.27976

Gozde Yazici, Serkan Akin, Alper Kahvecioglu, Ecem Yigit, Fatma Alev Turker, Ferah Yildiz

{"title":"The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas.","authors":"Gozde Yazici, Serkan Akin, Alper Kahvecioglu, Ecem Yigit, Fatma Alev Turker, Ferah Yildiz","doi":"10.1002/hed.27976","DOIUrl":null,"url":null,"abstract":"Background: This study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) ± systemic therapy.Methods: A retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted.Results: Most patients (87%) had early-stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow-up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five-year overall and disease-free survival (DFS) rates were 96.2% and 83.6%. Early-stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT-related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients.Conclusions: RT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early-stage patients.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27976","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) ± systemic therapy.

Methods: A retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted.

Results: Most patients (87%) had early-stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow-up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five-year overall and disease-free survival (DFS) rates were 96.2% and 83.6%. Early-stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT-related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients.

Conclusions: RT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early-stage patients.

查看原文本刊更多论文

放疗在偶发性眼附件和眼眶淋巴瘤中的作用。

背景：本研究评估了采用放射治疗（RT）±全身治疗方法治疗眼附件和眼眶淋巴瘤（OOLs）的肿瘤学结果和毒性：本研究评估了接受放射治疗（RT）和系统治疗的不显性眼附件和眼眶淋巴瘤（OOLs）的肿瘤学结果和毒性：方法：对44例接受RT治疗的不显性眼附件和眼眶淋巴瘤患者进行回顾性分析：结果：大多数患者（87%）为早期疾病。治疗方法包括单纯 RT（34%）或 RT + 全身治疗（66%）。中位 RT 剂量为 30 Gy，中位随访时间为 45 个月。局部和全身复发率分别为4%和9%。五年总生存率和无病生存率（DFS）分别为96.2%和83.6%。早期患者无论单独接受RT治疗还是RT加全身治疗，DFS率都相似。没有出现与RT相关的3级毒性，但17%的患者在接受全身治疗后出现了3级毒性：结论：RT是治疗不显性OOL的必要手段，与全身疗法联合使用并不能提高早期患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.